000171800 001__ 171800
000171800 005__ 20210129214315.0
000171800 0247_ $$2doi$$a10.1007/s00259-014-2934-0
000171800 0247_ $$2ISSN$$a0340-6997
000171800 0247_ $$2ISSN$$a1432-105X
000171800 0247_ $$2ISSN$$a1619-7070
000171800 0247_ $$2ISSN$$a1619-7089
000171800 0247_ $$2WOS$$aWOS:000349368700011
000171800 037__ $$aFZJ-2014-05362
000171800 082__ $$a610
000171800 1001_ $$0P:(DE-HGF)0$$aCornelius, Jan F.$$b0$$eCorresponding Author
000171800 245__ $$aUptake and tracer kinetics of O-(2-18F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results.
000171800 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2015
000171800 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1427449921_8798
000171800 3367_ $$2DataCite$$aOutput Types/Journal article
000171800 3367_ $$00$$2EndNote$$aJournal Article
000171800 3367_ $$2BibTeX$$aARTICLE
000171800 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000171800 3367_ $$2DRIVER$$aarticle
000171800 520__ $$aPurposeO-(2-[18F]Fluoroethyl)-l-tyrosine (18F-FET) is a well-established PET tracer for the imaging of cerebral gliomas, but little is known about 18F-FET uptake in meningiomas. The aim of this study was to explore 18F-FET kinetics and tumour-to-background contrast in meningiomas of various histologies.MethodsA group of 24 patients with suspected cerebral meningioma on MRI/CT had an additional dynamic 18F-FET PET scan prior to surgery. Time–activity curves (TAC) of 18F-FET uptake in the tumours and tumour-to-brain ratios (TBR) for early (3 – 14 min after injection) and late 18F-FET uptake (20 – 40 min after injection) were analysed and compared with histological subtypes and WHO grade. 18F-FET uptake in critical structures in the skull base was also evaluated in terms of tumour-to-tissue (T/Tis) ratio.ResultsTBR of 18F-FET uptake in meningiomas was significantly higher in the early phase than in the late phase (3.5 ± 0.8 vs. 2.2 ± 0.3; P < 0.001). The difference in TBR between low-grade meningiomas (WHO grade I, 18 patients) and high-grade meningiomas (WHO grade II or III, 6 patients) was significant in the late phase of 18F-FET uptake (2.1 ± 0.2 vs. 2.5 ± 0.2, P = 0.003) while there was no significant difference in the early phase. ROC analysis showed that TBR of 18F-FET uptake in the late phase had significant power to differentiate low-grade from high-grade meningiomas (AUC 0.87 ± 0.18, sensitivity 83 %, specificity 83 %, optimal cut-off 2.3; P < 0.01). Evaluation of TAC yielded three different curve patterns of 18F-FET PET uptake. Combination of TBR (cut-off value 2.3) and TAC pattern slightly improved the differentiation of high-grade from low-grade meningiomas (accuracy 92 %; P = 0.001). Analysis of background radioactivity in the skull base indicated that 18F-FET uptake may be helpful in distinguishing meningioma tissue in the late phase. T/Tis ratios were >1.2 in all patients for the periorbita, sphenoidal sinus, pituitary gland, tentorium, bone and brain, in more than 90 % of patients for the mucosa and dura, but in only 63 % of patients for the cavernous sinus.Conclusion18F-FET PET may provide additional information for noninvasive grading of meningiomas and possibly for the discrimination of tumour in critical areas of the skull base. A further evaluation of 18F-FET PET in meningiomas appears to be justified.
000171800 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000171800 588__ $$aDataset connected to CrossRef, juser.fz-juelich.de
000171800 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b1$$ufzj
000171800 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian$$b2
000171800 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b3
000171800 7001_ $$0P:(DE-HGF)0$$aSlotty, Philipp$$b4
000171800 7001_ $$0P:(DE-HGF)0$$aKamp, Marcel$$b5
000171800 7001_ $$0P:(DE-HGF)0$$ael Khatib, Mustafa$$b6
000171800 7001_ $$0P:(DE-HGF)0$$aHänggi, Daniel$$b7
000171800 7001_ $$0P:(DE-HGF)0$$aSabel, Michael$$b8
000171800 7001_ $$0P:(DE-HGF)0$$aFelsberg, Jörg$$b9
000171800 7001_ $$0P:(DE-HGF)0$$aSteiger, Hans Jakob$$b10
000171800 7001_ $$0P:(DE-Juel1)131816$$aCoenen, Heinrich Hubert$$b11
000171800 7001_ $$0P:(DE-Juel1)131794$$aShah, Nadim J.$$b12
000171800 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b13
000171800 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-014-2934-0$$n3$$p459-467$$tEuropean journal of nuclear medicine and molecular imaging$$v42$$x1619-7089$$y2015
000171800 8564_ $$uhttps://juser.fz-juelich.de/record/171800/files/art_10.1007_s00259-014-2934-0.pdf$$yRestricted
000171800 8564_ $$uhttps://juser.fz-juelich.de/record/171800/files/art_10.1007_s00259-014-2934-0.pdf?subformat=pdfa$$xpdfa$$yRestricted
000171800 909CO $$ooai:juser.fz-juelich.de:171800$$pVDB
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich GmbH$$b1$$kFZJ
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich GmbH$$b2$$kFZJ
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich GmbH$$b3$$kFZJ
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131816$$aForschungszentrum Jülich GmbH$$b11$$kFZJ
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich GmbH$$b12$$kFZJ
000171800 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich GmbH$$b13$$kFZJ
000171800 9130_ $$0G:(DE-HGF)POF2-333$$1G:(DE-HGF)POF2-330$$2G:(DE-HGF)POF2-300$$aDE-HGF$$bGesundheit$$lFunktion und Dysfunktion des Nervensystems$$vPathophysiological Mechanisms of Neurological and Psychiatric Diseases$$x0
000171800 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000171800 9141_ $$y2015
000171800 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000171800 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000171800 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000171800 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000171800 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000171800 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000171800 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000171800 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000171800 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000171800 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000171800 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000171800 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000171800 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000171800 980__ $$ajournal
000171800 980__ $$aVDB
000171800 980__ $$aI:(DE-Juel1)INM-3-20090406
000171800 980__ $$aI:(DE-Juel1)INM-4-20090406
000171800 980__ $$aI:(DE-Juel1)INM-5-20090406
000171800 980__ $$aUNRESTRICTED
000171800 981__ $$aI:(DE-Juel1)INM-4-20090406
000171800 981__ $$aI:(DE-Juel1)INM-5-20090406